Infectious Diseases

Anticipation rises for RSV rollout as positive data emerges

After record-high levels of respiratory syncytial virus (RSV) were seen in several countries, the pharmaceutical landscape for RSV infections has…

BioVaxys snatches up ‘bankrupt’ IMV’s preclinical and clinical assets

BioVaxys Technology has acquired the entire portfolio of discovery, preclinical and clinical assets along with the corresponding intellectual assets from…

MHRA agrees licence change for Pfizer-BioNTech’s Comirnaty vaccine

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for a variation in licence for Pfizer-BioNTech’s 30…

FDA accepts GSK’s RSV vaccine for adults aged 50-59 for review

The US Food and Drug Administration (FDA) has accepted for review a supplemental Biologics Licence Application to expand the usage…

Alternative therapies are needed to combat the impending threat of AMR

The potentially disastrous consequences of antimicrobial resistance (AMR) were highlighted at the recent World Economic Forum Meeting 2024. Antibiotic resistance…

Valneva sells Ixchiq priority voucher for $103m to fuel R&D

Valneva has sold its US Food and Drug Administration (FDA) priority review voucher for €95m ($103m) to an undisclosed party.…

As England’s virus hospitalisations surge flu vaccines evolve

England’s National Health Service (NHS) has revealed that flu cases last week were up 75% from the same period last…

GSK seeks to extend RSV vaccine use in adults aged 50-59

The European Medicines Agency (EMA) has accepted GSK’s regulatory application seeking expansion of its adjuvanted recombinant respiratory syncytial virus (RSV)…

MHRA approves Napp Pharmaceuticals’ Rezzayo for invasive candidiasis

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Napp Pharmaceuticals' new antifungal treatment for invasive candidiasis, Rezzayo…

Moderna leads the development of mRNA vaccines in infectious diseases

Currently, the global messenger RNA (mRNA) vaccines market consists entirely of vaccines for Covid-19. The rapid sequencing of the SARS-CoV-2…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close